Cardinal Health Inc Stock Price, News & Analysis

Cardinal Health (NYSE: CAH) has released its 2025 Advanced Therapies Report, providing comprehensive insights into the cell and gene therapy (CGT) industry. The report, based on a survey of over 100 healthcare providers, reveals that the advanced therapy industry is projected to have over 200 therapies approved and treat more than 100,000 U.S. patients by 2030.

Key findings highlight significant challenges in CGT adoption, with 56% of respondents citing financial constraints and 54% pointing to inadequate reimbursement as major barriers. The report emphasizes the need for improved collaboration across industry stakeholders, with 69% of respondents supporting strategic initiatives between payers and manufacturers. Additionally, 64% identified insufficient social support as the primary reason patients don't receive needed CGT treatments.

Cardinal Health (NYSE: CAH) has announced a dividend increase, with the new quarterly dividend set at $0.5107 per share. The dividend will be paid on July 15, 2025, to shareholders who are on record as of July 1, 2025. The payment will be made from the company's capital surplus.

Cardinal Health (NYSE: CAH) has announced it will release its third-quarter financial results for fiscal year 2025 on May 1, 2025, before the New York Stock Exchange opens. The company will host a webcast discussion of the results at 8:30 a.m. Eastern.

Investors can access the webcast and accompanying slide presentation through Cardinal Health's Investor Relations page without requiring an access code. The presentation materials and webcast replay will remain available on the company's Investor Relations page for 12 months following the event.

Cardinal Health (NYSE:CAH) has announced two significant additions to its Board of Directors, effective March 7, 2025. Robert Musslewhite, former CEO of Definitive Healthcare Corp., and Sudhakar Ramakrishna, current President and CEO of SolarWinds , have been elected as independent directors.

Musslewhite, with over 20 years of leadership experience, brings expertise in healthcare analytics and technology. He will serve on the board's Audit and Human Resources and Compensation Committees. Ramakrishna, a global technology leader with extensive cybersecurity experience, will join the Audit and Risk Oversight Committees.

Both appointments strengthen Cardinal Health's technological capabilities and strategic oversight. Musslewhite's background includes CEO roles at OptumInsight and The Advisory Board Company, while Ramakrishna's experience spans leadership positions at companies including Pulse Secure, Citrix Systems, and Polycom.

Cardinal Health (NYSE: CAH) has announced that its Board of Directors has approved a quarterly dividend payment. The company will distribute $0.5056 per share from its capital surplus. Shareholders who are recorded as owners at the close of business on April 1, 2025, will receive the dividend payment on April 15, 2025.

Cardinal Health (CAH) reported Q2 FY25 revenues of $55.3 billion, a 4% decrease from Q2 FY24, though revenue increased 16% excluding a large customer contract expiration. GAAP operating earnings rose 9% to $549 million, with GAAP diluted EPS at $1.65. Non-GAAP operating earnings grew 9% to $635 million, driven by Pharmaceutical and Specialty Solutions segment.

The company raised its FY25 non-GAAP EPS guidance to $7.85-$8.00 from $7.75-$7.90. Notable developments include completing acquisitions of 73% ownership in GI Alliance and Integrated Oncology Network. Pharmaceutical segment profit increased 7% to $531 million, while Global Medical Products segment profit rose to $18 million.